-
Dabrafenib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Dabrafenib Melanoma Novartis(GSK R&D) Jul.20, 2030 -
Dabigatran Etexilate Mesylate
API’s Name Indication Specification US DMF EU DMF CEP Dabigatran Etexilate Mesylate Anticoagulant In-House -
Daclatasvir Dihydrochloride
API’s Name Indication Specification US DMF EU DMF CEP Daclatasvir Dihydrochloride HCV In-House √ -
Doxycycline Monohydrate
API’s Name Indication Specification US DMF EU DMF CEP Doxycycline Mono Antibiotics USP/EP 18959 √ -
Doxycycline Hyclate
API’s Name Indication Specification US DMF EU DMF CEP Doxycycline Hyclate Antibiotics USP/EP 13771 √